ABSTRACT
SETTING: Centres participating in the Paediatric European Network for Treatment of AIDS (PENTA), including Thailand and Brazil. OBJECTIVE: To describe the incidence, presentation, treatment and treatment outcomes of tuberculosis (TB) in human immunodeficiency virus (HIV) infected children. DESIGN: Observational study of TB diagnosed in HIV-infected children in 2011-2013. RESULTS: Of 4265 children aged <16 years, 127 (3%) were diagnosed with TB: 6 (5%) in Western Europe, 80 (63%) in Eastern Europe, 27 (21%) in Thailand and 14 (11%) in Brazil, with estimated TB incidence rates of respectively 239, 982, 1633 and 2551 per 100 000 person-years (py). The majority (94%) had acquired HIV perinatally. The median age at TB diagnosis was 6.8 years (interquartile range 3.0-11.5). Over half (52%) had advanced/severe World Health Organization stage immunodeficiency; 67 (53%) were not on antiretroviral therapy (ART) at TB diagnosis. Preventive anti-tuberculosis treatment was given to 23% (n = 23) of 102 children diagnosed with HIV before TB. Eleven children had unfavourable TB outcomes: 4 died, 5 did not complete treatment, 1 had recurrent TB and 1 had an unknown outcome. In univariable analysis, previous diagnosis of acquired immune-deficiency syndrome, not being virologically suppressed on ART at TB diagnosis and region (Brazil) were significantly associated with unfavourable TB outcomes. CONCLUSION: Most TB cases were from countries with high TB prevalence. The majority (91%) had favourable outcomes. Universal ART and TB prophylaxis may reduce missed opportunities for TB prevention.
Subject(s)
Antibiotic Prophylaxis , Coinfection/epidemiology , HIV Infections/epidemiology , Tuberculosis/epidemiology , Antiretroviral Therapy, Highly Active , Antitubercular Agents/therapeutic use , Body Mass Index , Brazil/epidemiology , Child , Child, Preschool , Cohort Studies , Coinfection/drug therapy , Coinfection/prevention & control , Europe/epidemiology , Female , Follow-Up Studies , HIV Infections/drug therapy , Humans , Male , Prevalence , Risk Factors , Thailand/epidemiology , Tuberculosis/diagnosis , Tuberculosis/drug therapy , World Health OrganizationABSTRACT
The review summarizes experimental and clinical data about the influence of Lactobacillus on the immune system. A conclusion is made that the effect of Lactobacillus is a multifactor process. After entering the intestinal tract live microorganisms or biologically active substances produced by them may activate specific and nonspecific systems of microorganism protection. Experimental and clinical data about the action of Lactobacillus as adjuvants to the humoral immune response are presented. The mechanisms of anticancerogenic action of Lactobacillus and their cell wall components are analyzed in detail. The prospects for the use of Lactobacillus as probiotics in medicine are considered. The conclusion about positive value of the multifactor action of these microorganisms on the human immune system is made, since no negative effects are evoked by the discussed mechanisms of specific effect of Lactobacillus. This opens wide possibilities for the development of application schemes of probiotics from lactobacillus for the stimulation of several functions of the immune system, creation a new forms of antitumor drugs and combination of them with oral vaccines for improving their immunogenicity.